Neoadjuvant immunotherapy with the PD-1 inhibitor nivolumab is safe and feasible prior to surgery for early lung cancer, researchers reported at the ESMO 2016 Congress in Copenhagen. “Until now nivolumab and the other anti-PD-1 and anti-PD-L1 drug...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2djtR22
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: Available online 4 January 2018 Source: European Journal of Radiology Author(s): Peiyao Zhang, Jing Wang, Qin Xu, Zhen...
-
Background Hyperthyroidism is associated with increased thrombotic risk. As contact system activation through formation of neutrophil extrac...
-
Publication date: Available online 18 May 2016 Source: Cellular Signalling Author(s): José M. Muñoz-Félix, Cristina Cuesta, Nuria Perretta...
-
ACS Nano DOI: 10.1021/acsnano.7b02060 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2r2L7mh via...
-
The diffusion and adsorption behaviors of sodium and cesium were investigated in the Callovo-Oxfordian claystones (France) under unsaturated...
-
Abstract Ocean acidification increases the amount of dissolved inorganic carbon (DIC) available in seawater which can benefit photosynthes...
-
Abstract Over the past decades, an increasing need in renewable resources has progressively appeared. This trend concerns not only fossil f...
-
Zeinab Nazeeh Shata, Marwa R Amin, Heba M El-Kady, Mervat W Abu-Nazel Avicenna Journal of Medicine 2017 7(2):54-63 Background: Unlike ot...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου